Zoetis Completes Acquisition of VitalRADS, Boosting Diagnostic Services Amid Flattening Revenue

Zoetis on August 6 reported its second-quarter 2026 earnings, revealing flat revenue of $2.5 billion and adjusting guidance downward for full-year performance. At the same time, the company announced the completion of its acquisition of veterinary teleradiology provider VitalRADS, a strategic move aimed to enhance its diagnostics capabilities beyond in vitro testing. These developments mark a notable evolution in Zoetis’ focus on strengthening its diagnostic services in response to softening companion animal markets.

Second‑Quarter Results and Guidance Revision

For Q2 2026, Zoetis reported revenue of $2.5 billion, essentially unchanged from the same quarter last year, equating to a 1 % decline on an organic operational basis. Net income was $691 million, or $1.65 per diluted share, down 5 % from the prior year, while adjusted net income was $781 million, or $1.87 per diluted share. Adjusted figures decreased 1 % and 2 % on reported and organic operational bases, respectively. In response, full-year guidance was revised: organic operational revenue growth of –3 % to –1 %, and organic operational adjusted net income growth of –9 % to –5 %, reflecting a more cautious outlook amid macro pressures. 

Zoetis attributed weakness in its U.S. companion animal segment to lower clinic visits, price sensitivity, and heightened competition across key categories like dermatology and parasiticides. However, growth was underpinned by strength in livestock products, particularly in cattle and poultry, and continued momentum in international diagnostics and companion animal launches such as Lenivia® and Portela™, long-acting monoclonal antibody treatments for osteoarthritis pain. 

Completion of VitalRADS Acquisition Enhances Diagnostic Strategy

During the same quarter, Zoetis completed the acquisition of VitalRADS, a provider of veterinary teleradiology services and cloud-based imaging solutions. VitalRADS offers 24/7 access to board-certified veterinary radiologists and specialists across modalities—radiographs, CT, MRI, ECG—and supports over 1,800 customers through services including mobile ultrasound and outpatient imaging. Its VitalPACS system integrates cloud-based image archiving with veterinary medical records. The acquisition, expected to close in the third quarter of 2026, builds on a prior partnership and is designed to accelerate Zoetis’ Virtual Reference Laboratory strategy. 

This complements Zoetis’ existing point-of-care and AI-enabled tools, such as Vetscan Imagyst® and Vetscan Opticell™, enabling the company to deliver a more complete diagnostics solution combining specialist interpretation, AI-assisted workflows, and reference capabilities. The move expands Zoetis’ presence across both diagnostics and therapeutics at a time when companion-animal demand shows signs of softness. 

Strategic Implications for Zoetis and Investors

The acquisition of VitalRADS marks a clear acceleration in Zoetis’ diagnostics strategy—moving toward a unified, AI-enabled Virtual Reference Lab capable of supporting healthcare providers with richer, faster interpretation services. This diversification may help offset stagnation in its traditional companion animal segment by leveraging growth in diagnostics and livestock markets.

However, the company’s revised guidance underscores ongoing headwinds in the companion animal space, particularly in the U.S. Investors should weigh the potential long-term upside from enhanced diagnostic offerings against near-term margin pressure. Continued execution on integration, uptake of tools like Lenivia® and Portela™, and momentum in diagnostics adoption will be key variables to monitor. 

As of August 24, 2026, Zoetis (NYSE: ZTS) traded at $77.17, down 0.54 %.

Looking Ahead

Zoetis’ strengthened diagnostics ecosystem, anchored by VitalRADS and AI-powered imaging tools, positions the company to better serve veterinary practices across diagnostics needs. The success of this strategy will hinge on integration efficiency, client adoption rates, and Zoetis’ ability to innovate amid evolving demand dynamics. Investors should observe upcoming updates on diagnostics utilization, pipeline progression, and how the company navigates the cooling companion animal market in the second half of 2026.